<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3526">
  <stage>Registered</stage>
  <submitdate>19/04/2012</submitdate>
  <approvaldate>19/04/2012</approvaldate>
  <nctid>NCT01582269</nctid>
  <trial_identification>
    <studytitle>A Study in Recurrent Glioblastoma (GB)</studytitle>
    <scientifictitle>A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent Glioblastoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>H9H-MC-JBAL</secondaryid>
    <secondaryid>13849</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Glioblastoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Brain</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - LY2157299 monohydrate
Treatment: drugs - Lomustine
Treatment: drugs - Placebo

Experimental: LY2157299 monohydrate plus lomustine - 300 mg/day LY2157299, given orally for 14 days, followed by 14 days of rest, equaling a 28-day cycle.
First lomustine dose will be given as 100 mg/m2 on day 7 cycle 1. Remaining doses are based on the investigator's discretion and will be given orally once every 6 weeks in capsules to equal 100 to 130 mg/m2.

Experimental: LY2157299 monohydrate - 300 mg/day LY2157299, given orally for 14 days, followed by 14 days of rest, equaling a 28-day cycle (unblinded)

Active Comparator: lomustine plus placebo - First lomustine dose will be given as 100 mg/m2 on day 7 cycle 1. Remaining doses are based on the investigator's discretion and will be given orally once every 6 weeks in capsules to equal 100 to 130 mg/m2.
LY2157299 monohydrate-matched placebo, given orally as tablets for 14 days, followed by 14 days of rest, equaling a 28-day cycle.


Treatment: drugs: LY2157299 monohydrate
Orally administered as tablets

Treatment: drugs: Lomustine
Orally administered as capsules

Treatment: drugs: Placebo
Orally administered as tablets

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Date of randomization to date of death from any cause estimated up to 2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Population Pharmacokinetics (PK): median population clearance</outcome>
      <timepoint>Cycle 1, Day 1, 3, 14, 15 and 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival (PFS)</outcome>
      <timepoint>Randomization to the date of objective progression or death from any cause estimated up to 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with Tumor Response</outcome>
      <timepoint>Every 2 cycles to disease progression or participant starts a new anticancer therapy estimated up to 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in neurocognitive function</outcome>
      <timepoint>Baseline, cycle 1, cycle 2 then every 2 cycles to 30 day post discontinuation follow up estimated up to 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Population Pharmacokinetics (PK): absorption</outcome>
      <timepoint>Cycle 1, Day 1, 3, 14, 15 and 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Population Pharmacokinetics (PK): volume of distribution</outcome>
      <timepoint>Cycle 1, Day 1, 3, 14, 15 and 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) score</outcome>
      <timepoint>Baseline, cycle 1, cycle 2 then every 2 cycles to 30 day post discontinuation follow up estimated up to 2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histological confirmed diagnosis of relapsed intracranial GB

          -  Progressive Disease (PD) following standard chemoradiation

          -  Prior surgical resection allowed

          -  Performance status Eastern Cooperative Oncology Group (ECOG) 0 or 1

          -  Adequate hematologic, hepatic and renal function

          -  Discontinued all prior cancer treatments for cancer &amp; recovered from the acute effects
             of therapy

          -  Tumor specimen must be available for a central pathology review and prognostic and
             predictive biomarker evaluation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Moderate or severe heart disease based on New York Heart Association (NYHA) criteria

          -  Prior nitrosurea therapy (including lomustine or Gliadel)

          -  Prior bevacizumab as 1st line treatment for GB (if treatment was concluded 12 months
             prior to enrollment, the patient may be eligible to participate in the trial)

          -  Current acute or chronic myelogenous leukemia

          -  Second primary malignancy that may affect the interpretation of results

          -  Serious concomitant systemic disorder</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>180</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - St. Leonards</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Heidelberg</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Parkville</hospital>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Li√®ge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bobigny</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Terni</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Udine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299
      plus lomustine therapy or lomustine plus placebo can help participants with brain cancer</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01582269</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>